Loading...

APC anti-mouse CD103 Antibody

Pricing & Availability
Clone
2E7 (See other available formats)
Regulatory Status
RUO
Other Names
Integrin αIEL chain, Integrin αE chain, αE integrin, ITGAE
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
2E7_APC_121508.jpg
BALB/c splenocytes stained with 2E7 APC
  • 2E7_APC_121508.jpg
    BALB/c splenocytes stained with 2E7 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
121413 25 µg 86€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
121414 100 µg 261€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD103 is a type I transmembrane glycoprotein known as αE integrin or Integrin αIEL chain. It belongs to the integrin family and is primarily found on intestinal intraepithelial lymphocytes (IEL). CD103 is also expressed on a subpopulation of lamina propria T cells, epithelial dendritic cells, lamina propria-derived dendritic cells, and a small subset of peripheral lymphocytes. T regulatory cells express high level of CD103. The CD103 expression on lymphocytes can be induced upon activation and TGF-β stimulation. In association with integrin β7, CD103 is expressed as αE/β7 heterodimer. Mature CD103 protein can be cleaved into 2 chains, a 150 kD (C-terminal) chain and a 25 kD (N-terminal) chain, which remain linked by disulfide bonds. CD103 binds to E-cadherin and mediates homing of lymphocytes to the intestinal epithelium.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse intestinal intraepithelial lymphocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining1,7 of acetone-fixed frozen sections, immunofluorescence2, and in vitro activation1.

Application References

(PubMed link indicates BioLegend citation)
  1. LeFrancois L, et. al, 1994. Eur. J. Immunol. 24:635. (FC, IHC, IP)
  2. Mysorekar IU, et. al, 2002. J. Biol. Chem. 277:37811. (FC, IF)
  3. Mikami N, et al. 2011. J. Immunol. 186:6886. PubMed
  4. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  5. Quinn KM, et al. 2013. J. Immunol. 191:5085. PubMed
  6. Verhagen J and Wraith DC. 2014. J. Immunol. Methods. S0022. (FC) PubMed
  7. Xiao B, et al. 2015. PLoS One 1:e0115333. (IHC)
Product Citations
  1. Koyama M, et al. 2015. J Exp Med. 212: 1303 - 1321. PubMed
  2. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  3. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  4. Kimura S, et al. 2020. Nat Commun. 0.620833333. PubMed
  5. Peng C, et al. 2022. Immunity. 55:98. PubMed
  6. Liu L, et al. 2022. Nat Commun. 13:6740. PubMed
  7. Fiege JK, et al. 2021. Cell Host Microbe. 29:1815. PubMed
  8. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  9. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  10. Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed
  11. Fachi JL et al. 2019. Cell reports. 27(3):750-761 . PubMed
  12. Dong L, et al. 2021. Cancer Cell. . PubMed
  13. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  14. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
  15. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  16. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  17. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  18. Rao S, et al. 2017. Cell. 168(3):503-516.e12. PubMed
  19. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  20. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  21. Fujita Y et al. 2018. Cell reports. 24(12):3296-3311 . PubMed
  22. Kawakami R, et al. 2021. Immunity. 54(5):947-961.e8. PubMed
  23. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  24. Wu L, et al. 2022. Theranostics. 12:842. PubMed
  25. Cassidy BR, et al. 2020. J Neuroinflammation. 17:259. PubMed
  26. Gozgit JM, et al. 2021. Cancer Cell. :. PubMed
  27. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  28. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  29. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  30. Gabriel SS, et al. 2021. Immunity. 54(8):1698-1714.e5. PubMed
  31. Jin C, et al. 2019. Cell. 176:998. PubMed
  32. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  33. Jin C, et al. 2022. Oncoimmunology. 11:2099642. PubMed
  34. Yamada D, et al. 2014. J Immunol. 192:4112. PubMed
  35. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  36. Kim M, et al. 2018. Immunity. 49:151. PubMed
  37. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  38. Amezcua Vesely MC, et al. 2020. Cell. 178(5):1176-1188.e15.. PubMed
  39. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  40. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  41. Stefan KL, et al. 2020. Cell. 1312:183. PubMed
  42. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  43. Li J, et al. 2021. Cell Reports. 34(11):108839. PubMed
  44. Yu H, et al. 2015. PLoS One. 10: 0143001. PubMed
  45. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  46. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  47. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  48. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  49. Chng S, et al. 2016. Sci Rep. 6: 23820. PubMed
  50. Paiva C, et al. 2010. Rheumatology. 49:246. PubMed
  51. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  52. Pan Y, et al. 2021. NPJ Vaccines. 6:1. PubMed
RRID
AB_1227502 (BioLegend Cat. No. 121413)
AB_1227502 (BioLegend Cat. No. 121414)

Antigen Details

Structure
Type I transmembrane glycoprotein, Integrin family, can be cleaved into 150 kD and 25 kD chains, associated with β7 integrin
Distribution

Majority of intestinal intraepithelial lymphocytes (IEL), subpopulation of lamina propria T cells, epithelial dendritic cells, small subset of peripheral lymphocytes, Treg cells.

Function
Retention and activation of CD103+ lymphocytes in the intestinal epithelium, regulate tissue-specific T cell homing.
Ligand/Receptor
E-Cadherin
Cell Type
Dendritic cells, Lymphocytes, T cells, Tregs
Biology Area
Immunology
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Kilshaw PJ and SJ. Murant. 1990. Eur. J. Immunol. 20:2201.
2. Karecla PI, et al. 1995. Eur. J. Immunol. 25:852.
3. LeFrancois L, et al. 1994. Eur. J. Immunol. 24:635.
4. Sung SS, et al. 2006. J. Immunol. 176:2161.
5. Johansson-Lindbom B, et al. 2005. J. Exp. Med. 202:1063.
6. Dujardin HC, et al. 2004. Proc. Natl. Acad. Sci. USA. 101:14473.

Gene ID
16407 View all products for this Gene ID
UniProt
View information about CD103 on UniProt.org
Go To Top Version: 2    Revision Date: 05/04/2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account